Aims: Stroke is a major cause of mortality and disability, especially for postmenopausal women. In view of the protective action of estrogen, hormone therapy remains the only effective way to limit this risk. The objective of this study was to investigate the efficiency and underlying mechanisms of estrogen neuroprotection.
effect in stroke is still under debate. Numerous studies performed in humans and animals have shown beneficial action of estrogen therapy for stroke, whereas other clinical studies, such as the Women's Health Initiative, found that estrogen treatment failed to confer neuroprotection and even increased the susceptibility for stroke. 4, 5 Although the window of opportunity hypothesis has been proposed to explain the conflicting results, 6, 14, 15 this discrepancy is still unclear. Moreover, given the extended life expectancy, contemporary women spend more time of their lives in a hypoestrogenic state, and it makes women more vulnerable to hormone-related diseases. Therefore, it becomes even more important to confirm the efficiency of estrogen and probe the potential mechanisms.
Ischemic stroke is the most common type of stroke. 16, 17 In this pathology, brain energy exhaustion and metabolic stress aggravate the brain cell death under ischemic stress and determine the outcome of acute brain injury. 2 Therefore, the defense to energy exhaustion is an effective strategy to protect ischemic stroke. AMP-activated protein kinase (AMPK) is recognized as a major metabolic energy sensor, which is activated in response to decreased cellular energy charge (increased in AMP/ATP ratio) and further regulates energy metabolic homeostasis. [18] [19] [20] [21] Silent mating type information regulation 2 homolog 1 (SIRT1) is also implicated in the regulation of energy metabolism, insulin sensitivity, and longevity. 22, 23 The SIRT1-dependent AMPK pathway was reported to protect against ischemic stroke in the action of resveratrol and Nampt. 2, 24, 25 Estrogen was demonstrated to regulate SIRT1/AMPK/epigenetic modifications to prevent cardiovascular dysfunction in postmenopausal women with metabolic syndrome.
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Despite the role of estrogen as a neuroprotectant in stroke is well established, [27] [28] [29] [30] [31] [32] [33] estrogen's contribution to energy exhaustion after ischemic injury is less studied.
This study aimed to validate the role of estrogen against stroke damage in vivo and in vitro, and discover the underlying pathway mediation of such neuroprotection effect.
| MATERIALS AND METHODS

| Animals
Female Sprague-Dawley (SD) rats and C57 mice were purchased from Sino-British SIPPR/BK Lab Animals (Shanghai, China). Female SIRT1 knockout mice and littermate wild-type (WT) mice were obtained from the Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, the Chinese Academy of Sciences. Controlled temperature (23-25°C) and lighting (8:00 am-8:00 pm light, other time dark) were offered for the animals, as well as free access to standard food and drinking water.
| Ovariectomy (OVX) and estrogen replacement
To establish estrogen deficiency and estrogen replacement conditions, the rodents were divided into three groups: sham group (with vehicle), OVX group (with vehicle), and OVX+E (with 17β-estradiol).
OVX was performed by dorsolateral incision, as previously described. 29 Briefly, after the animals were anesthetized, both the right and left horns of the uterus were exposed through two small lateral abdominal incisions. The ovaries were then carefully removed, leaving the uterus intact. Animals in the sham groups were subjected to the same operation, with the exception that the ovaries were left intact. Five days after OVX, the animals began receiving daily subcutaneous injections of estrogen (500 μg/kg in rats and mice, diluted in sesame oil solution) or vehicle at the back of the neck for 28 days.
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To confirm effectiveness of estrogen deficiency and replacement, the levels of serum estrogen were measured. Briefly, the animals were anesthetized with an overdose of pentobarbital sodium, and blood was collected from the ophthalmic artery. Serum levels of estrogen, progestin, and testosterone were measured using ELISA kit purchased from Xi-Tang BioTech (shanghai, China).
To observe the effect of estrogen deficiency and replacement on neurons, the serums of three groups were used to treat neurons. Blood samples were collected from the carotid artery using a polyethylene catheter which was inserted into the carotid artery under anesthesia, as previously described. 1 Then, serum was inactivated by heating in water bath for 30 minutes.
In addition, after OVX and estrogen treatment, some animals were subjected to middle cerebral artery occlusion (MCAO) and some were killed to examine morphometric parameters. At sacrifice, the heart, kidney, liver, and uterus were removed and weighed.
| Middle cerebral artery occlusion (MCAO)
The animals were anesthetized with chloral hydrate (300 mg/kg), and then, MCAO surgery in rats was performed as described. 16 Two hours after MCAO, the occluding filament was withdrawn to allow reperfusion. Twenty-four hours after MCAO, rats were killed for various examinations after neurological deficit scoring.
Permanent focal cerebral ischemia in mice was induced by cauterizing the left middle cerebral artery using methods described previously. 34 Focal ischemia was produced by permanent occlusion of the left middle cerebral artery by electrocoagulation.
Neurological deficits in MCAO rodents were examined using a 5-point scale as described. 16 The infarct size expressed as a percentage of the contralateral hemisphere was determined by 2,3,5-triphenyltetrazolium chloride (TTC) staining as described. 
| Neuron culture
Primary rat and mouse neuronal cells were cultured from the cerebral cortex of neonatal animals within 6 hours after birth, as described previously. 16 One day after isolation, Neurobasal medium (Invitrogen, Carlsbad, CA, USA) supplemented with 2% B27 (Invitrogen) was used to replenish the cultures. Uridine (10 μmol/L) was added to suppress glial growth. After 7-day culture in vitro, cultured cells were stained for NeuN (neuron marker, Millipore, Billerica, CA, USA) to access the proportion of neurons (>90%), and then, the neurons were treated with drugs, prior to oxygen-glucose deprivation. 
| Oxygen-Glucose Deprivation (OGD) Model and cell injury assay
| Real-time PCR
To analyze the level of the SIRT1 mRNAs in neurons, real-time PCR was performed as previously described. 16 Total RNA was extracted from neurons using TRIzol (Invitrogen) and reverse-transcribed into cDNA using the RevertAid™ First-Strand cDNA Synthesis Kit (Fermentas, Lithuania). Then, the mRNA levels were evaluated by appropriate specific primers and the SYBR Green RT-PCR Kit (Takara, Japan), with cDNA as the template. The following primer pairs (Takara, Japan)
were used: SIRT1 sense (5′-GCTGACGACTTCGACGACG-3′) and antisense (5′-TCGGTCAACAGGAGGTTGTCT-3′); and GAPDH sense (5′-GTATGACTCCACTCACGGCAAA-3′) and antisense (5′-GGTCTC GCTCCTGGAAGATG-3′). The expression levels of the target-gene mRNA transcripts were normalized relative to GAPDH controls.
| Immunoblotting
The total protein from cells was prepared as described. 16 The fol- Then, IRDye 800CW-conjugated secondary antibody (Rockland, Gilbertsville, PA, USA) was incubated.
| Reagents and drugs
Anti-SIRT1, anti-Ace-H3, anti-p-AMPK, and anti-AMPK antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA).
Anti-p-ACC, anti-ACC, anti-ERα, and antiactin antibodies were purchased from Abcam (Cambridge, MA, USA).
17β-estradiol, ERα-specific inhibitor methyl-piperidino-pyrazole (MPP), and AMPK-inhibitor Compound C were purchased from SigmaAldrich (St Louis, MO, USA). Estrogen receptor β (ERβ)-specific inhibitor (R,R)-THC was purchased from Tocris Bioscience (Avonmouth, Bristol, UK).
After 7-day culture in vitro, the neurons were treated with estrogen 
| Statistical analysis
The investigators were blinded to the procedures, including assessing the infarct size and neurological deficit score of MCAO animals. The random permutation table was used to randomly assign the animals.
Data are expressed as the mean±SD and analyzed with two-tailed Student's t test or one-way analysis of variance (ANOVA). P<.05 is considered statistically significant.
| RESULTS
| Estrogen supplement significantly increased serum estrogen levels and attenuated weight gain induced by OVX
Serum estrogen levels were measured to confirm the efficacy of estrogen supplement in SD rats. As shown in Figure 1A , the serum estrogen levels in the OVX rats were decreased by 50.6% compared with the sham-operated rats, suggesting estrogen deficiency. Serum estrogen levels in the OVX+E groups were 1.88 times greater than those in the OVX group, which was similar to those in the sham group, suggesting successful estrogen replacement therapy. We also measured other hormone levels. OVX significantly decreased the levels of progesterone and testosterone by 50.9% and 63.8%, respectively, and estrogen supplement did not change the levels of progesterone and testosterone ( Figure 1B-C) .
Morphometric parameters were listed in Table 1 . Rats had an increased body weight after OVX, and estrogen replacement therapy reversed this effect of body weight gain. Absolute weights of heart, kidney, and liver were comparable among the groups. The OVXmediated increase in uterine weight was restored by estrogen treatment, consistent with its known effects.
| Estrogen supplement conferred neuroprotection
To determine the effect of estrogen supplement on ischemic stroke, experiments were performed using MCAO rats. (Figure 4) . 
| SIRT1 was essential for estrogen-induced neuroprotection
In cultured primary neurons, estrogen increased SIRT1 expression in a dose-effect manner under OGD, and 1×10 −5 mol/L estrogen upregulated SIRT1 expression to its peak level ( Figure 5A ). Apart from this, a significant decrease in Ace-H3, a known downstream target of SIRT1, was observed in neurons of estrogen treatment, indicating that estrogen increased SIRT1 deacetylase activity. Because studies of AMPK adopted the 1×10 −6 mol/L estrogen, in which dosage SIRT1 expression and activity were significantly increased, we also used These data indicate that the SIRT1 plays an important role in estrogenevoked neuron survival.
To further define the role of SIRT1, WT and SIRT1 −/− mice were subjected to MCAO. In WT mice, estrogen supplement reduced infarction volume by 30.2%, compared with the OVX group. This effect of estrogen was significantly attenuated in SIRT1 −/− mice ( Figure 6 ).
These data in vivo and vitro indicate that the SIRT1 is essential for estrogen-induced neuroprotection.
| SIRT1 was essential for estrogen-induced AMPK activation
Given that estrogen regulated AMPK activation by ERα, whether ERα can directly interact with AMPK was determined in neurons using an immunoprecipitation assay. Our data did not show a direct interaction between these two proteins ( Figure 7A ). These results indicated that the absence of SIRT1 impairs the estrogen activation of AMPK in neurons under OGD.
In contrast, AMPK inhibition by Compound C did not hamper the upregulation of SIRT1 induced by estrogen, suggesting that SIRT1 upregulation by estrogen is independent of AMPK activation ( Figure 7D ).
| DISCUSSION
Our data clearly showed that estrogen replacement protects against ischemic damage in MCAO rats and in OGD neurons. Furthermore, we demonstrated that SIRT1-AMPK signaling pathway is involved in the beneficial effect of estrogen under cerebral ischemic stress. Utilizing both pharmacological and genetic manipulations, this study showed that estrogen protects against ischemic stroke, through upregulation of SIRT1 expression and activity, thus promoting AMPK activation, further regulating energy exhaustion, and contributing to neuron survival under ischemic stress.
To our knowledge, discrepant results of experimental studies were reported as to the effect of estrogen on stroke. [27] [28] [29] [30] [31] [32] [33] Regarding the reason, except for the complex effect of estrogen in brain, the timing, duration, dosage, and route of administration are critical parameters in determining the effect. This dichotomized outcome has been analyzed in a recent systematic review and meta-analysis. 28 It suggested that subcutaneous injections, which generated estrogen concentrations of 10-110 pg/mL, showed consistent neuroprotection. Consistent with this analysis, in our study, the dosages of estrogen were within this range, and such neuroprotection was confirmed.
The brain consumes more energy per gram of tissue than any other organ. 34 Neuronal ischemia, the consequence of a stroke, confers en- Estrogen has well-documented neuroprotective effects in many clinical and experimental cerebral ischemia caused by stroke. [14] [15] [16] [17] [27] [28] [29] Previous mechanisms of estrogen as a neuroprotectant focus on oxidative stress, inflammation, apoptosis, and vascular modulation, much less on energy exhaustion after ischemic injury. Estrogen was previously reported to regulate SIRT1 and AMPK in many cells and rodents. [35] [36] [37] [38] [39] [40] [41] Moreover, estrogen prevents cardiovascular dysfunction in postmenopausal metabolic syndrome through SIRT1/AMPK pathway. 22 In view of the above studies, we hypothesized that "SIRT1-AMPK" signaling pathway may play a key role in neuroprotection of estrogen. As expected, we observed that estrogen upregulated the ex- SIRT1. 42 According to our results, estrogen-induced neuroprotection was abolished in SIRT1 −/− mice, indicative of a key role of SIRT1, consistent with previous study. However, as to the mechanism of estrogen-regulating SIRT1, we only observed mRNA and protein level of SIRT1. It is known that estrogens exert their effects via several different pathways, including the classical nuclear receptors ER-α and ER-β, membrane-linked receptors, and other direct molecular mechanisms. Thus, taking account of the diversity and complexity of estrogen pathway, as well as our inadequate study performed in this point, our result was not contradictory with previous study. We believe that PARP-1 may be an upstream target of SIRT1, which involves in the action of estrogen. It remains to be investigated in the future.
Regarding SIRT1 and AMPK pathway, some previous studies suggested that AMPK lies upstream of SIRT1, 43, 44 which was different from our study. Auwerx J and colleagues reported that AMPK regulated energy expenditure by modulating SIRT1 activity in myocytes, 43 which is very different from the central nervous system. Pan TH and colleagues demonstrated that AMPK-SIRT1-autophagy pathway involved in the neuroprotection of resveratrol on Parkinson cellular models, 42 which is not ischemic stress pathology. The difference in pathology model and cell type may account for the dichotomized discrepancy of pathways.
In our study, SIRT1 upregulation by estrogen in OGD neurons was not affected by AMPK inhibition, indicating that estrogen upregulating SIRT1 during ischemic stress is not driven by AMPK in neurons.
Although important discoveries were revealed in our study, there are also limitations. First, we did not assess estrogen level in brain.
Estrogen acting on nervous tissue can be divided into two classes, those which are peripherally synthesized and then penetrate the blood-brain barrier and those which synthesized de novo within the brain. Peripherally, serum estrogen level was monitored in our study;
however, it only represents a crude estimate of the concentrations in the brain, where the actual effects take place. Secondly, estrogens exert their effects via several different pathways, and the pathway beyond the classical nuclear receptors was not studied, such as membranelinked receptors and direct molecular mechanisms. Thirdly, estrogen was measured on one occasion during the experiment, which provides little information about the serum concentrations fluctuation during the study. Fourthly, the concentrations of estrogens determined by in vitro experiments are several orders of magnitude higher than in vivo experiments and therefore hard to interpret to in vivo conditions.
In conclusion, this study demonstrated that estrogen protects against ischemic stroke, through rescuing neurons from death via the SIRT1-dependent AMPK pathway. Our results provide new sights into estrogen mechanisms in ischemic stroke and suggest that SIRT1-AMPK pathway is a therapeutic target for stroke prevention for postmenopausal women.
